Management believes it can drastically cut down the time and cost to bring drugs to market. The company is involved with multiple clinical trials, but none of them are in late stages just yet. Its ...
Investing personality Jim Cramer recently called Recursion Pharmaceuticals a meme stock. The facts don't back up that position, though. Recursion may not be a meme stock, but that doesn't make it a ...
Recursion Pharmaceuticals (RXRX) shares rallied 7.4% in the last trading session to close at $11.93. This move can be attributable to notable volume with a higher number of shares being traded than in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results